An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Advanced or Recurrent Epithelial Ovarian Cancer

This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells in patients with advanced or recurrent epithelial ovarian cancer

开始日期2021-03-30

申办/合作机构

Pharmicell Co., Ltd.

NCT03838250 / Unknown status临床1期

A Phase I, Open-Label, Single-Dose Study to Evaluate the Safety and Efficacy of Hepatic Artery Injection of Autologous Human Bone Marrow-Derived Mesenchymal Stem Cells (Cellgram™) in Patients With Alcoholic Liver Cirrhosis

This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.

开始日期2019-06-20

申办/合作机构

Pharmicell Co., Ltd.

100 项与 Cellgram-DC 相关的临床结果

登录后查看更多信息

100 项与 Cellgram-DC 相关的转化医学

登录后查看更多信息

100 项与 Cellgram-DC 相关的专利（医药）

登录后查看更多信息

项与 Cellgram-DC 相关的文献（医药）

2012-11-01·Clinical and Experimental Immunology3区 · 医学

Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination within-situdendritic cell vaccination in advanced lymphoma

3区 · 医学

Article

作者: Haimovich, J ; Hollander, N ; Cohen, S ; Manzur, S

SummaryThe present standard of care for B cell non-Hodgkin's lymphoma includes the anti-CD20 monoclonal antibody rituximab. Although combination treatments with chemotherapy and rituximab improved the duration of remissions and overall survival in indolent B cell lymphoma, the disease is essentially incurable. Thus, new therapeutic approaches are needed. One such approach is active immunization. Given that rituximab depletes both malignant and normal B cells, it is expected to impair humoral immune responses in vaccinated patients. Hence, optimal vaccination strategies for rituximab-treated patients require induction of effector T cells, which can be achieved by dendritic cell (DC) vaccines. We have demonstrated in a mouse model that chemotherapy combined with DC vaccines was therapeutically effective. However, efficacy was related to tumour size at the onset of treatment, decreasing in correlation with increasing tumour burdens. We therefore examined whether, in spite of its low efficacy in advanced disease, DC vaccination may synergize with anti-CD20 antibodies to enhance therapy. Lymphoma-bearing mice were treated with cyclophosphamide, anti-CD20 antibodies and an intratumoral DC vaccine. Results clearly demonstrated the enhanced therapeutic effect of this combination treatment. Thus, under conditions of disseminated disease, when either anti-CD20 antibody treatment or vaccination showed insufficient efficacy, their combination resulted in synergism that mediated long-term survival. We demonstrated further that the combination of antibody and vaccine induced T cell-mediated anti-tumour immune responses with long-term memory. Combination treatments including tumour cell-loaded DC vaccines may therefore provide a strategy for enhancing therapy in rituximab-treated patients.

1998-04-01·Journal of immunology (Baltimore, Md. : 1950)

Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection.

Article

作者: Celluzzi, C M ; Falo, L D

Dendritic cells (DCs) are potent professional APCs capable of presenting Ag in the context of costimulatory signals necessary for T cell activation. Although tumor cells express target Ags, they are generally incapable of stimulating an immune response. We show that the short term physical interaction of DCs and tumor cells, with or without cell fusion, results in rapid, efficient, and stable DC-tumor cell association. Immunization of naive mice with unselected, irradiated DC-tumor cell conjugates induces tumor-specific CD8+ cytotoxic T cells and protection from lethal tumor challenge. Furthermore, the immunogenicity of this cellular vaccine is dependent on the physical interaction of DCs and tumor cells before injection. Immunization with DCs and tumor cells after physical interaction can result in the regression of established tumors and persistent antitumor immunity. These results suggest that immunization with DC-tumor cell vaccines may be a simple, rapid, and potent strategy for tumor immunotherapy.

100 项与 Cellgram-DC 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性卵巢癌	临床1期	韩国	Pharmicell Co., Ltd.	2021-03-30
去势抵抗性前列腺癌	临床1期	韩国	Pharmicell Co., Ltd.	2020-12-01
胰腺癌	临床1期	韩国	Pharmicell Co., Ltd.	2020-11-08